Cardiac Wire

@Cardiac_Wire

The cardiology news you need, beat by beat. Subscribe: http://cardiacwire.com/subscribe/

Joined March 2022

156Following

899Followers

Cardiac Wire@Cardiac_Wire · Jul 25

The Society of Cardiovascular Computed Tomography had its 20th annual meeting in the gorgeous city of Montreal and though it’s still intimate, the conference punches well above its weight class when it comes to innovation. cardiacwire.com/the-top-trends…

Cardiac_Wire's tweet card. The Society of Cardiovascular Computed Tomography had its 20th annual meeting in the gorgeous city of Montreal and though it's still intimate, the conference punches well above its weight class when...

116

Cardiac Wire Retweeted

TeraRecon@TeraRecon · Jul 24

In the latest episode of The @Cardiac_Wire Show, discover how AI and advanced visualization are transforming cardiac imaging workflows today, and empowering physicians to dedicate more time to what truly matters—patient care! Watch now: hubs.ly/Q03yMrCk0

Cardiac Wire@Cardiac_Wire · Jul 22

A new JACC study revealed that broader adoption of single-pill combination therapies (aka polypills) containing multiple cardiovascular medications could significantly transform global health trends by 2050 and potentially lower the burden of future CVD. cardiacwire.com/cv-polypills-c…

Cardiac_Wire's tweet card. A new JACC study revealed that broader adoption of single-pill combination therapies (aka polypills) containing multiple cardiovascular medications could significantly transform global health trends...

Cardiac Wire@Cardiac_Wire · Jul 18

The FDA approved Bayer’s KERENDIA (finerenone) for treating heart failure patients with left ventricular ejection fraction ≥40%, marking the first new pharmaceutical option for HF in years. cardiacwire.com/its-official-f…

Cardiac_Wire's tweet card. One of the hardest-to-treat cardiac conditions just got a little more hopeful as the FDA approved Bayer’s KERENDIA (finerenone) for treating heart failure patients with left ventricular ejection...

Cardiac Wire@Cardiac_Wire · Jul 1

Foldax’s polymer-based TRIA Mitral Valve replacement showed compelling one-year results in its India Clinical Trial presented at New York Valves 2025, suggesting we could soon have an alternative to bovine tissue valves. cardiacwire.com/foldaxs-tria-m…

Cardiac_Wire's tweet card. The valve replacement space keeps adding contenders, and Foldax’s polymer-based TRIA Mitral Valve replacement showed compelling one-year results in its India Clinical Trial presented at New York...

Cardiac Wire@Cardiac_Wire · Jun 27

A recent AHA study suggests there could be a link between ocean microplastic levels and cardiovascular disease in U.S. coastal counties, adding to a concerning trend of microplastics and CV risk. cardiacwire.com/save-the-plane…

Cardiac_Wire's tweet card. We’ve all cut down on plastic straws to save the sea turtles, but what about ourselves? A recent AHA study suggests there could be a link between ocean microplastic levels and cardiovascular disease...

Cardiac Wire@Cardiac_Wire · Jun 26

In the latest Cardiac Wire, we discuss… 🫀Save the Planet to Save Our Hearts (From Microplastics) 🫀EnCompass’ First F2 Patient 🫀J&J Anti-Trust Plot Thickens And more #cardiology news. Check it out below. #CardioTwitter #MedTwitter cardiacwire.com/newsletter/mic…

Cardiac_Wire's tweet card. Microplastics impact CVD, J&J gets hit with an injunction, Novo breaks up with Hims & Hers, and plenty more cardiovascular news!

Cardiac Wire@Cardiac_Wire · Jun 24

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. cardiacwire.com/edwards-evoque…

Cardiac_Wire's tweet card. Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that...

299